R Package Validation for Regulatory Submissions

Introduction

R is increasingly used for clinical-trial data processing, statistical analysis, visualization, reporting, and automation. In a regulated environment, however, the question is not simply whether an R script runs successfully.

The more important question is whether the computerized process used for the intended purpose is sufficiently controlled, tested, documented, reproducible, and traceable to support the reliability of the resulting clinical-trial outputs.

This changes the way a statistical programmer should think about validation. A package cannot be made "regulatory" merely by installing it, running a few examples, or documenting that it is open source. Conversely, validation does not necessarily require independently reimplementing every mathematical algorithm in every dependency.

What Does R Package Validation Mean?

In ordinary software development, a programmer might install a package, run unit tests, and begin using it. In a regulated clinical-trial environment, that is only part of the story.

Suppose an analysis uses:

• R 4.x
• survival
• lme4
• emmeans
• dplyr
• a sponsor-developed package
• a controlled analysis dataset
• a predefined analysis program

The validated object is not simply "the survival package." It is the defined configuration and intended use that produces the analysis result.

Validation Is Not the Same as Testing

Testing asks whether particular behavior works. Validation is broader.

Why Regulatory Agencies Care About Computerized Systems

FDA guidance on computerized systems used in clinical investigations emphasizes confidence that data generated or processed by computerized systems are reliable and that computerized processes are appropriately controlled. FDA's more recent 2024 guidance on electronic systems, electronic records, and electronic signatures in clinical investigations also addresses the trustworthy and reliable use of electronic systems and records.

EMA's guideline on computerized systems and electronic data in clinical trials similarly describes validation as a lifecycle activity and emphasizes a risk-based approach. Importantly, the responsible party remains accountable for the validation of systems used in the trial even when vendor documentation is used as evidence.

R Package Validation Is Usually Risk-Based

Not every package or function needs the same amount of validation effort.

Consider two uses of ggplot2:

• A draft exploratory plot used internally to investigate an endpoint.
• A production figure included in a regulatory submission and generated from a controlled analysis dataset.

The software may be identical, but the intended use and risk are different.

A useful conceptual model is:

This is not a regulatory formula. It is a practical way to explain why a high-impact production analysis deserves more evidence than an exploratory script.

What Makes a Function High Risk?

A Practical Validation Lifecycle

Step 1: Define Intended Use

The intended-use statement should be specific enough that another person can understand what is being validated.

For a package, document the intended use by function or functional area where appropriate. A package may contain hundreds of functions, but only a subset may be used in the regulated workflow.

Step 2: Identify the Validation Boundary

A critical question is: what exactly are we claiming to have validated?

Step 3: Perform a Risk Assessment

A simple risk register can classify software components by their effect on the analysis.

Step 4: Requirements

Requirements should be testable. A good requirement has a clear condition and expected behavior.

Requirements Should Be Traceable

A traceability matrix connects the requirement to the test and the resulting evidence.

Unit Testing With testthat

testthat is useful for automated software tests. It is not, by itself, a complete regulatory validation framework.

library(testthat)

pct_change <- function(aval, base) {
  if (is.na(base) || base == 0) {
    return(NA_real_)
  }
  (aval - base) / base * 100
}

test_that("percentage change is calculated correctly", {
  expect_equal(pct_change(75, 100), -25)
  expect_equal(pct_change(120, 100), 20)
})

test_that("zero baseline is handled explicitly", {
  expect_true(is.na(pct_change(10, 0)))
})

test_that("missing baseline is handled explicitly", {
  expect_true(is.na(pct_change(10, NA_real_)))
})

These tests demonstrate normal and boundary behavior. For production validation, the test specification should be linked to approved requirements and the execution should generate retained evidence.

Test Categories That Matter

Independent Reference Results

One of the strongest approaches for statistical validation is comparison against an independently generated expected result.

For example, if an R function calculates a confidence interval, the expected result might be generated independently using:

• a separately implemented formula;
• an independently qualified statistical system;
• a validated reference dataset with known results;
• published numerical examples; or
• a mathematically derived expected value.

Example: Independent Verification of a Mean

Suppose the controlled test data are:

The expected mean is:

The R implementation can then be tested against that independently known value.

test_that("mean matches the approved reference result", {
  x <- c(10, 12, 14, 16, 18)
  expect_equal(mean(x), 14)
})

This is simple, but the same principle scales to survival estimates, mixed-model parameters, LS-means, confidence intervals, responder counts, and derived endpoints.

Reference Datasets

A validation package should contain controlled datasets designed to exercise the important behaviors of the software.

Package Dependencies Are Part of the Problem

R packages rarely operate alone. A package may depend on dozens of other packages, system libraries, compiled code, or external resources.

If a production analysis depends on:

R
├── dplyr
│   ├── rlang
│   ├── vctrs
│   └── tibble
├── survival
└── emmeans
    ├── estimability
    └── mvtnorm

then the versions and configuration of those dependencies can affect the reproducibility of the analysis.

Use renv to Record the R Environment

renv can create a project-level dependency lockfile. A typical workflow is:

install.packages("renv")
renv::init()

# After installing approved packages:
renv::snapshot()

# Recreate the environment elsewhere:
renv::restore()

The resulting renv.lock records package information needed to reconstruct the project environment.

Record More Than Package Versions

For a high-impact regulated workflow, consider controlling:

• R version
• operating system or container image
• package versions
• source repository commit or release identifier
• compiler/toolchain where relevant
• system libraries where relevant
• environment variables
• locale and encoding
• time-zone configuration
• random-number-generation settings
• configuration files
• input dataset versions
• analysis specification version

Why Random Number Generation Matters

Some clinical-trial workflows use simulation, bootstrap procedures, multiple imputation, Bayesian computation, resampling, or other stochastic methods.

For these analyses, reproducibility may require controlling:

• the random seed;
• the random-number generator kind;
• the number and order of random draws;
• parallel execution behavior;
• package versions that influence RNG behavior.

set.seed(20260910)

result <- replicate(
  1000,
  mean(sample(1:100, size = 20, replace = TRUE))
)

A controlled stochastic analysis should document the reproducibility strategy rather than assuming that setting a seed alone guarantees identical results across every software environment.

Floating-Point Results and Tolerances

Numerical software can produce tiny differences across platforms or implementations even when the statistical result is effectively equivalent.

Therefore, validation tests sometimes require a justified numerical tolerance.

expect_equal(
  actual,
  expected,
  tolerance = 1e-10
)

The tolerance should be scientifically and technically justified. It should not be chosen merely to make a failed test pass.

Snapshots and Golden Files

For complex outputs, exact numerical assertions are not always convenient. Snapshot-style testing can capture structured output and compare future runs against an approved baseline.

test_that("model summary is unchanged", {
  fit <- lm(y ~ x, data = ref_data)
  expect_snapshot(summary(fit))
})

Snapshot tests are useful for detecting unintended changes, but a snapshot is not automatically a scientifically correct expected result. The original reference output still needs to be reviewed and approved.

Hashing Outputs and Inputs

Cryptographic hashes can help demonstrate that a file or artifact has not changed since it was recorded.

tools::md5sum("analysis_dataset.xpt")

tools::md5sum("renv.lock")

For stronger modern integrity workflows, organizations may use SHA-256 or another approved hashing mechanism outside base R.

Source-Code Control

Production validation should identify the exact source code used to generate the result.

A useful identifier might be:

Repository: clinical-analysis
Branch: release/2026.09
Commit: 7f4d1c2
Analysis specification: SAP v3.1
Dataset: ADTTE v1.4
Environment: renv.lock SHA-256 ...

Do not rely solely on a mutable folder named final. A controlled release should identify an immutable version or commit.

Git Helps, but Git Is Not Validation

Version control provides valuable evidence about source-code history, but simply storing R scripts in Git does not establish that the scripts are validated.

Validating Third-Party Packages

A common question is: "Do we have to validate every function in every CRAN package?"

Usually, that is the wrong framing.

A more useful sequence is:

1. Which package functionality is actually used?
2. What regulated function does it support?
3. What is the risk if it fails?
4. What evidence exists from the package maintainer?
5. What independent verification can the sponsor perform?
6. What version is controlled?
7. What happens if the package changes?

Vendor or open-source documentation can be useful evidence, but it does not automatically transfer accountability for the sponsor's intended use.

Example: Validating survival::coxph()

Suppose a clinical study uses a Cox proportional-hazards model for a key endpoint.

The package function may be mature and extensively used. A risk-based validation strategy could still include:

• controlled package version;
• known reference dataset;
• reference coefficient estimates;
• reference standard errors;
• reference hazard ratios;
• reference confidence intervals;
• comparison with an independent implementation;
• tests for event/censoring coding;
• tests for ties handling;
• tests for strata and covariates if used;
• documentation of intended use and limitations.

library(survival)

fit <- coxph(
  Surv(time, status) ~ treatment + age,
  data = reference_data
)

summary(fit)

# Example validation assertions:
expect_equal(
  unname(coef(fit)["treatmentB"]),
  expected_beta,
  tolerance = 1e-8
)

Example: Validating Mixed Models

Mixed-effects models can be more challenging because results depend on model specification, optimization, convergence, covariance structure, numerical tolerances, and package implementation.

For a high-impact mixed-model analysis, validation may need to cover:

• fixed effects;
• random effects;
• variance components;
• estimated marginal means;
• contrasts;
• confidence intervals;
• convergence status;
• singular-fit behavior;
• missing-data handling;
• optimization settings.

For example:

library(lme4)

fit <- lmer(
  change ~ treatment * visit + baseline + (1 | subject),
  data = reference_data,
  REML = FALSE
)

stopifnot(isTRUE(lme4::isSingular(fit, tol = 1e-4)) == expected_singular)

# Compare key coefficients with approved reference results.
expect_equal(
  fixef(fit),
  expected_fixef,
  tolerance = 1e-7
)

The exact tolerance and validation design should reflect the model and the approved statistical specification.

Integration Testing

Unit tests test functions individually. Regulatory analysis pipelines also need integration testing.

For example:

A pipeline can pass every unit test while still failing at an integration boundary—for example, because a variable was renamed, a date was interpreted incorrectly, or a factor level was reordered.

Interface Validation

Interfaces between systems deserve explicit attention.

Data Integrity and R

Validation is closely related to data integrity. A statistically correct algorithm can still produce an unacceptable result if the input data are wrong, altered, incomplete, or not traceable to the approved source.

For a submission workflow, consider the complete chain:

21 CFR Part 11 Is Not an R Package Validation Standard

21 CFR Part 11 concerns electronic records and electronic signatures in specified regulated contexts. It is important in regulated computerized environments, but it should not be treated as a checklist titled "R package validation."

The practical questions are broader:

• Are the relevant electronic records trustworthy and reliable?
• Are systems and processes appropriately controlled?
• Can changes be detected and managed?
• Can records be retained and retrieved appropriately?
• Can the organization demonstrate what software and configuration produced a result?
• Are electronic signatures and access controls handled under the applicable procedures?

Audit Trails and Source-Code History

Source-code history can support traceability, but a Git log is not necessarily equivalent to a regulated audit trail. Organizations should define which records are controlled, how changes are reviewed and approved, and how relevant evidence is retained.

Validation Documentation

A practical validation package for an R-based statistical component might include:

Validation Plan Example

Document: R Statistical Environment Validation Plan
System: Oncology Analysis R Environment
Version: 1.0

Intended use:
  Production statistical analysis and reporting for defined clinical-trial
  endpoints using approved analysis datasets.

In scope:
  R version 4.x
  Approved package versions
  Sponsor-developed analysis package
  Defined statistical functions
  Reproducible analysis pipeline

Out of scope:
  Exploratory notebooks
  Unapproved package functionality
  Developer-local environments

Risk approach:
  High-risk statistical functions receive independent reference testing.
  Lower-risk formatting utilities receive representative functional tests.

Acceptance criteria:
  All critical tests pass or have approved, documented dispositions.
  The production environment can be reconstructed from controlled artifacts.
  All requirements are traceable to executed tests and evidence.

Test Case Design

A test case should be reproducible by someone other than its author.

Negative Testing

Validation should test how software behaves when users supply invalid or unexpected inputs.

test_that("missing treatment variable fails clearly", {
  expect_error(
    run_analysis(
      data = subset(reference_data, select = -treatment)
    )
  )
})

For regulated workflows, a controlled error is often preferable to silent behavior.

Testing Clinical-Trial Derivations

Statistical software validation is not sufficient if the clinical derivation itself is wrong.

Suppose an endpoint requires:

• baseline defined as the last nonmissing assessment before first dose;
• post-baseline measurements after first dose;
• a specific analysis visit window;
• a particular imputation rule.

The validation suite should test those business and statistical rules explicitly.

test_that("baseline is selected according to the specification", {
  result <- derive_baseline(reference_data)

  expect_equal(
    result$baseline_value[result$USUBJID == "001"],
    100
  )
})

Boundary Testing for Clinical Thresholds

Thresholds are especially important in clinical-trial programming because an off-by-one or rounding error can change a response category or analysis population.

Rounding Is a Validation Issue

Do not round intermediate values unless the statistical specification explicitly requires it.

# Prefer retaining precision internally
estimate <- calculate_estimate(data)

# Round only for presentation
formatted <- sprintf("%.2f", estimate)

For example, an estimate of 1.23495 might display as 1.23 or 1.24 depending on the formatting rule. The underlying analysis should not be changed simply because the display rounds the number.

Dates and Time Zones

Clinical-trial analyses often depend on dates and relative days. Date handling should therefore be part of validation.

as.Date("2026-01-15")

difftime(
  as.Date("2026-02-12"),
  as.Date("2026-01-15"),
  units = "days"
)

For workflows involving timestamps, daylight saving time, or cross-region execution, validate the time-zone assumptions explicitly.

Factor Levels and Treatment Ordering

R factors can materially affect statistical models and displays.

data$treatment <- factor(
  data$treatment,
  levels = c("Control", "Treatment")
)

levels(data$treatment)

Validation should confirm that the reference treatment is correct and that contrasts, model coefficients, tables, and plots use the intended ordering.

Missing Data

Missing-value behavior is one of the most important validation topics in clinical programming.

Test:

• missing baseline;
• missing covariates;
• missing endpoint;
• partial records;
• missing visit dates;
• all-missing treatment groups;
• intermittent longitudinal missingness;
• records removed by analysis-population criteria.

Parallel Processing

Parallel execution can affect reproducibility, logging, random-number generation, and even numerical results in some workflows.

If production code uses parallel processing, validate the controlled parallel configuration and document any known reproducibility implications.

Performance Testing

Performance is not always a validation requirement, but it can become one when an analysis must complete within an operational window or when resource exhaustion could cause incomplete execution.

For example, test:

• small reference dataset;
• representative production-scale dataset;
• large stress dataset;
• memory usage;
• runtime;
• failure behavior under insufficient resources.

Reproducibility Testing

A powerful validation test is to rebuild the environment from scratch and rerun the same analysis.

This is especially valuable for detecting hidden dependencies on developer-local settings.

What Counts as Objective Evidence?

Good validation evidence is reproducible, attributable, and linked to a defined test.

Validation Report

The validation report should answer a simple question: Did the defined system meet the defined acceptance criteria for the intended use?

A concise report structure is:

1. Purpose and scope
2. System and intended use
3. Risk assessment summary
4. Environment
5. Requirements
6. Test execution summary
7. Failures and deviations
8. Impact assessments
9. Traceability status
10. Residual risk
11. Conclusion
12. Approvals

Example Validation Conclusion

This is an example of wording, not a universal regulatory conclusion. The actual conclusion must reflect the study's procedures, evidence, deviations, and quality-system requirements.

Change Control

Validation is not a one-time event. A package upgrade can change numerical results, defaults, dependency behavior, or output formatting.

Examples of changes requiring impact assessment include:

• R version upgrade;
• package upgrade;
• package downgrade;
• operating-system change;
• container-image change;
• compiler change;
• source-code modification;
• analysis-specification change;
• new dependency;
• dependency removal.

Example Change-Control Workflow

What If a Package Upgrade Changes a Result?

Suppose version 1.4 of a package produces a treatment estimate of 1.25 and version 1.5 produces 1.27.

The correct response is not to automatically choose the version with the preferred answer.

Instead:

1. Confirm that the change is real and reproducible.
2. Identify the cause.
3. Determine whether the new result is correct.
4. Assess whether previously generated analyses are affected.
5. Determine whether the change requires reanalysis.
6. Document the decision.

Regression Testing

A regression suite should contain the tests most likely to detect material changes in validated functionality.

# Example regression command
Rscript -e 'testthat::test_dir("tests/testthat")'

# Example environment capture
R.version.string
sessionInfo()

For a production environment, capture the execution result in the controlled validation record rather than relying only on a developer terminal.

Package Unit Tests vs Sponsor Validation Tests

Independent Programming QC

For important submission outputs, an independent programmer or independent method can provide strong evidence.

For example, one programmer may generate a table in R and another may independently reproduce key statistics using a separate implementation or independently written code.

The goal is not necessarily to duplicate every line of source code. The goal is to provide independent evidence that critical results are correct.

Dual Programming Is Not Always Required for Every R Function

A risk-based strategy can distinguish between:

• critical endpoint derivations;
• complex model calculations;
• high-impact population filters;
• formatting functions;
• noncritical exploratory utilities.

The required level of independent verification should be defined by the applicable quality system and risk assessment.

Validating Visualization Packages

Figures can be regulated outputs even though their underlying calculations are not always complex.

Validation should consider:

• correct data population;
• correct x/y variables;
• correct treatment assignment;
• correct reference lines;
• correct axis units;
• correct labels and legends;
• correct censoring or event markers;
• correct rounding;
• correct page size and output format.

For a critical figure, compare the final rendered output with an approved reference and reconcile the underlying data used to construct it.

Output Validation

Output validation should occur at two levels:

Submission Traceability

A strong regulated workflow can trace a final output backward:

This is more valuable than simply saying "the table was produced in R."

What Inspectors May Want to Understand

An inspector or auditor may reasonably ask:

• What system produced this output?
• What version was used?
• How was the system validated?
• What was the intended use?
• What requirements were tested?
• What were the acceptance criteria?
• Were there deviations?
• How was the environment controlled?
• How are changes managed?
• Can you reproduce the result?
• How do you know the critical calculations are correct?
• Can you trace the result to the underlying data and source code?

Common Mistakes

1. "It's on CRAN, so it is validated." CRAN availability is not sponsor-specific validation.
2. "The package has unit tests, so we are done." Package tests are useful evidence but do not necessarily cover the sponsor's intended use.
3. "We validated R itself." Avoid broad claims that exceed the evidence.
4. "We tested one example." One successful example rarely covers boundaries, missing data, invalid inputs, or integration.
5. "The numbers look right." Visual plausibility is not a substitute for defined acceptance criteria.
6. "The developer's machine is the environment." Local configuration is not a controlled production baseline.
7. "A lockfile validates the analysis." It controls configuration; it does not establish statistical correctness.
8. "A hash proves the result is correct." A hash proves identity/integrity, not correctness.
9. "We can upgrade packages whenever we want." Production changes should follow impact assessment and change control.
10. "We can regenerate the reference result with the same code." That creates circular evidence.
11. "We only need to validate the final PDF." Output inspection is important, but the underlying calculations and data flow also require appropriate controls.
12. "Validation is finished when the report is signed." The validated state must be maintained through the software lifecycle.

Recommended R Validation Project Structure

r-validation/
├── DESCRIPTION
├── NAMESPACE
├── R/
│   ├── analysis_functions.R
│   ├── derivations.R
│   └── formatting.R
├── tests/
│   └── testthat/
│       ├── test-derivations.R
│       ├── test-statistics.R
│       ├── test-boundaries.R
│       └── test-errors.R
├── reference-data/
│   ├── REF-001-basic.csv
│   ├── REF-002-missing.csv
│   └── REF-003-boundaries.csv
├── reference-results/
│   ├── REF-001-results.csv
│   └── REF-002-results.csv
├── validation/
│   ├── validation-plan.pdf
│   ├── risk-assessment.xlsx
│   ├── requirements.csv
│   ├── traceability.csv
│   ├── test-protocol.pdf
│   └── validation-report.pdf
├── renv.lock
└── README.md

Example: A Minimal Sponsor Validation Package

For a small but controlled R component, a reasonable starting package might contain:

Validation vs. Qualification

Terminology varies among organizations and quality systems. Some organizations distinguish computer-system qualification activities such as installation, operational, and performance qualification from software validation. Others use a broader computerized-system validation lifecycle.

For clinical-trial statistical programming, the important point is to follow the organization's approved terminology and procedures rather than inventing a parallel vocabulary for R.

How R Packages Fit Into a Computerized-System Lifecycle

Validation of Open-Source Software

Open-source software introduces a different evidence model from a commercial vendor product.

You may have access to:

• source code;
• package tests;
• release notes;
• issue trackers;
• documentation;
• peer-reviewed publications;
• large user communities.

These can all support a risk-based assessment. They do not eliminate the need to determine whether the specific version and intended use are appropriate.

When to Revalidate

There is no single universal event list that automatically determines revalidation for every R environment. The applicable quality system and risk assessment should define the trigger.

Common triggers include:

• material R upgrade;
• material package upgrade;
• change in statistical algorithm;
• change in dependency;
• change in operating environment;
• material bug fix;
• change in intended use;
• new regulated functionality;
• discovery of a software defect affecting validated outputs.

Defect Management

When validation identifies a defect, document more than the fact that the test failed.

Validation and Clinical Programming QC

Validation does not replace normal clinical-programming QC.

A Practical End-to-End Example

Imagine a randomized oncology study with a time-to-event primary endpoint. The production workflow uses R to generate a Kaplan–Meier figure and Cox-model table.

1. Intended use

Generate the prespecified primary time-to-event analysis from the approved ADTTE dataset.

2. Risk

High, because the outputs support a primary endpoint in a regulatory submission.

3. Software

R, survival, sponsor-developed analysis functions, and controlled reporting code.

4. Requirements

Define event coding, censoring, analysis population, model covariates, confidence interval method, display rules, and output formatting.

5. Reference results

Establish independently reviewed coefficient estimates, hazard ratio, confidence interval, number of events, and selected survival probabilities.

6. Automated tests

Test normal cases, censoring, ties, missing values, treatment ordering, boundaries, and output structure.

7. Integration test

Run the complete pipeline from controlled input to final table and figure.

8. Environment control

Restore the exact R and package versions from the approved environment specification.

9. Review

Compare critical outputs to independent reference results and perform final output QC.

10. Release

Archive the source, environment, inputs, outputs, test evidence, and approval records according to the applicable procedures.

Example Validation Checklist

Submission-Ready Environment Manifest

A concise manifest can make an R analysis easier to reconstruct.

Study: ABC-001
Analysis: Primary PFS Analysis
Analysis specification: SAP v3.1
R version: 4.x.x
OS/container: approved production image
Package environment: renv.lock
Source revision: 7f4d1c2
Input dataset: ADTTE v1.4
Input hash: SHA-256 ...
Analysis execution ID: RUN-2026-09-10-001
Validation baseline: RVAL-2026.09
Test suite status: PASS
Critical deviations: None open
Approval status: Approved

What a Strong R Validation Strategy Looks Like

A mature strategy has several characteristics.

The Most Important Concept

The most important conceptual shift is this:

An R package can be excellent software and still require sponsor-specific validation evidence. Conversely, a sponsor does not necessarily need to independently validate every line of a large dependency when a focused, risk-based strategy can establish confidence in the functions actually used.

The objective is a defensible chain from intended use → risk → requirements → controlled environment → testing → objective evidence → approval → change control.

References and Regulatory Reading

FDA. Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers. Final Guidance for Industry, October 2024.
FDA. Guidance for Industry: Computerized Systems Used in Clinical Investigations.
FDA. Part 11, Electronic Records; Electronic Signatures — Scope and Application. Guidance for Industry, September 2003.
FDA. Electronic Source Data in Clinical Investigations. Guidance for Industry, September 2013.
FDA. Data Integrity and Compliance With Drug CGMP: Questions and Answers. Guidance for Industry, December 2018.
EMA. Guideline on computerised systems and electronic data in clinical trials. EMA/INS/GCP/112288/2023, 2023.
ICH. E6 Good Clinical Practice and applicable computerized-system validation principles.

This tutorial is educational material, not legal, regulatory, quality-system, or validation advice for a specific sponsor. Applicable requirements depend on the jurisdiction, product, trial, records involved, computerized-system lifecycle, and the organization's approved procedures. Always use the current applicable regulations, guidance, SOPs, and quality-system requirements when establishing a production validation strategy.